Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNDX
stocks logo

SNDX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
64.08M
+734.42%
-0.583
-46.97%
70.79M
+253.22%
-0.542
-44.69%
85.54M
+125.36%
-0.432
-47.95%
Estimates Revision
The market is revising Downward the revenue expectations for Syndax Pharmaceuticals, Inc. (SNDX) for FY2025, with the revenue forecasts being adjusted by -1.08% over the past three months. During the same period, the stock price has changed by 15.85%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.08%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.98%
In Past 3 Month
Stock Price
Go Up
up Image
+15.85%
In Past 3 Month
Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 36.00 USD with a low forecast of 22.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 36.00 USD with a low forecast of 22.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.740
sliders
Low
22.00
Averages
36.00
High
56.00
Current: 19.740
sliders
Low
22.00
Averages
36.00
High
56.00
Barclays
NULL
to
Overweight
upgrade
$22 -> $35
2025-11-24
Reason
Barclays
Price Target
$22 -> $35
2025-11-24
upgrade
NULL
to
Overweight
Reason
Barclays raised the firm's price target on Syndax to $35 from $22 and keeps an Overweight rating on the shares. The firm updated the company's model after speaking with management.
JPMorgan
Anupam Rama
Overweight
downgrade
$40 -> $33
2025-11-12
Reason
JPMorgan
Anupam Rama
Price Target
$40 -> $33
2025-11-12
downgrade
Overweight
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Syndax to $33 from $40 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
UBS
Buy
maintain
$35 -> $38
2025-11-04
Reason
UBS
Price Target
$35 -> $38
2025-11-04
maintain
Buy
Reason
UBS raised the firm's price target on Syndax to $38 from $35 and keeps a Buy rating on the shares.
Barclays
Peter Lawson
Overweight
maintain
$19 -> $22
2025-11-04
Reason
Barclays
Peter Lawson
Price Target
$19 -> $22
2025-11-04
maintain
Overweight
Reason
Barclays analyst Peter Lawson raised the firm's price target on Syndax to $22 from $19 and keeps an Overweight rating on the shares. The company's "softer" Q3 was well telegraphed by management, and the focus can now turn to Q4 and Q1, with expectations for stronger growth, the analyst tells investors in a research note. The firm cites approval in NPM1 and better traction of Niktimvo for the target bump.
H.C. Wainwright
NULL -> Buy
initiated
$40
2025-10-16
Reason
H.C. Wainwright
Price Target
$40
2025-10-16
initiated
NULL -> Buy
Reason
H.C. Wainwright assumed coverage of Syndax with a Buy rating and $40 price target. The firm has conviction that Revuforj will expand its footprint across the relapsed/refractory setting. Revuforj is emerging as the foundational menin inhibitor in acute myeloid leukemia, the analyst tells investors in a research note.
Stifel
NULL
to
Buy
initiated
$44
2025-09-10
Reason
Stifel
Price Target
$44
2025-09-10
initiated
NULL
to
Buy
Reason
Stifel resumed coverage of Syndax with a Buy rating and $44 price target. The firm believes the commercial launches of two of the company's assets create a path to non-GAAP profitability in the second half of fiscal 2026. Each asset has $1B-plus in peak sales potential and are still in the very early stages of growth, the analyst tells investors in a research note. Stifel views Syndax's valuation as compelling at current levels.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Syndax Pharmaceuticals Inc (SNDX.O) is -10.47, compared to its 5-year average forward P/E of -7.77. For a more detailed relative valuation and DCF analysis to assess Syndax Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.77
Current PE
-10.47
Overvalued PE
-2.42
Undervalued PE
-13.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.15
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.72
Undervalued EV/EBITDA
-10.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
354.98
Current PS
0.00
Overvalued PS
1103.69
Undervalued PS
-393.72
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 195.05% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 195.05% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SNDX News & Events

Events Timeline

(ET)
2025-11-03
16:16:27
Syndax anticipates steady operating expenses in the coming years.
select
2025-11-03
16:15:06
Syndax announces Q3 earnings per share of 70 cents, slightly below consensus estimate of 71 cents.
select
2025-11-03
09:23:01
Syndax Reveals Acceptance of Revuforj and Niktimvo Data for ASH 2025 Presentation
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-17Yahoo Finance
JPMorgan Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $33, Keeps "Overweight" Rating Intact

  • Syndax Pharmaceuticals Overview: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is recognized as a promising small-cap biotech stock, with analysts highlighting its potential for significant upside.

  • Recent Financial Performance: In Q3 2025, Syndax reported a 21% revenue increase to $45.9 million, driven by strong sales of its therapies, particularly Revuforj, which gained FDA approval for a broader patient population.

  • Price Target Adjustment: JPMorgan adjusted its price target for Syndax from $40 to $33 while maintaining an "Overweight" rating, reflecting changes in their models for the SMID-cap biotechnology sector.

  • Future Projections: The company ended the quarter with $456 million in cash and projected R&D costs of $380 to $385 million for the year, indicating a solid financial position to support ongoing operations and development.

[object Object]
Preview
6.0
11-04Benzinga
UBS Reiterates Buy Rating for Syndax Pharmaceuticals and Increases Price Target to $38

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.

  • Market Winning Tools: Benzinga Pro is designed to help traders gain an edge in the markets with accurate stock market intelligence.

[object Object]
Preview
9.0
11-04SeekingAlpha
Syndax aims for $10B market following Revuforj's NPM1 approval and a 21% increase in Q3 revenue.

  • Management Performance: CEO Michael Metzger reported a strong Q3 2025 with total revenue of $45.9 million, driven by successful launches of Revuforj and Niktimvo, and highlighted Revuforj's FDA approval for NPM1 mutated AML, significantly expanding its market potential.

  • Financial Results: Revuforj generated $32 million in net revenue, while Niktimvo contributed $45.8 million, with Syndax's share being $13.9 million. The company maintains a solid financial position with $456 million in cash and investments.

  • Growth Outlook: Management anticipates accelerated sales growth due to the recent FDA approval and plans to expand Revuforj and Niktimvo into frontline settings, targeting a combined market opportunity exceeding $10 billion.

  • Analyst Sentiment: Analysts expressed positive interest but focused on execution details and market penetration, while management remained confident about their commercial strategy and path to profitability amidst potential risks related to payer mix and competition.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Syndax Pharmaceuticals Inc (SNDX) stock price today?

The current price of SNDX is 19.74 USD — it has increased 0.15 % in the last trading day.

arrow icon

What is Syndax Pharmaceuticals Inc (SNDX)'s business?

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

arrow icon

What is the price predicton of SNDX Stock?

Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 36.00 USD with a low forecast of 22.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Syndax Pharmaceuticals Inc (SNDX)'s revenue for the last quarter?

Syndax Pharmaceuticals Inc revenue for the last quarter amounts to 45.87M USD, increased 266.97 % YoY.

arrow icon

What is Syndax Pharmaceuticals Inc (SNDX)'s earnings per share (EPS) for the last quarter?

Syndax Pharmaceuticals Inc. EPS for the last quarter amounts to -0.70 USD, decreased -28.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Syndax Pharmaceuticals Inc (SNDX)'s fundamentals?

The market is revising Downward the revenue expectations for Syndax Pharmaceuticals, Inc. (SNDX) for FY2025, with the revenue forecasts being adjusted by -1.08% over the past three months. During the same period, the stock price has changed by 15.85%.
arrow icon

How many employees does Syndax Pharmaceuticals Inc (SNDX). have?

Syndax Pharmaceuticals Inc (SNDX) has 270 emplpoyees as of December 05 2025.

arrow icon

What is Syndax Pharmaceuticals Inc (SNDX) market cap?

Today SNDX has the market capitalization of 1.72B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free